Elevated serum liver-type fatty acid binding protein levels in non-acetaminophen acute liver failure patients with organ dysfunction.
Fiche du document
2 novembre 2020
- handle: 10670/1.0dx6q1
- doi: 10.1007/s10620-020-06166-w
Mots-clés
Acute liver failure Liver-type fatty acid binding protein Multiorgan failure Prognosis ALFSG indexSujets proches
Blood--Serum Blood serum Days of the weekCiter ce document
Constantine J. Karvellas et al., « Elevated serum liver-type fatty acid binding protein levels in non-acetaminophen acute liver failure patients with organ dysfunction. », Papyrus : le dépôt institutionnel de l'Université de Montréal, ID : 10.1007/s10620-020-06166-w
Métriques
Partage / Export
Résumé
Liver-type fatty acid binding protein (FABP1) has previously been demonstrated to improve prognostic discrimination in acetaminophen (APAP)-induced ALF but has not been investigated in other etiologies of ALF. AIM: To determine whether FABP1 levels (early: admission or late: days 3-5) are associated with 21-day transplant-free survival in non-APAP ALF. METHODS: FABP1 was measured in serum samples from 384 ALF patients (n = 88 transplant-free survivors (TFS), n = 296 died/LT-NTFS) using solid-phase enzyme-linked immunosorbent assay and analyzed with US ALFSG registry data. RESULTS: Of 384 ALF patients (autoimmune hepatitis n = 125, drug-induced liver injury n = 141, Hepatitis B n = 118), 177 (46%) patients received LT. Early FABP1 levels were significantly higher in ALF patients requiring vasopressor support (203.4 vs. 76.3 ng/mL) and renal replacement therapy (203.4 vs. 78.8 ng/mL; p